http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2331260-C
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a933a0dd561e3e50b278738704d5c6e6 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-702 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-00 |
| filingDate | 1999-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2008-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6fc67da86f5e119a3c80d3391fa6e8d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26b4cc0b8d9dfec173d30ee734748759 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1521656fcd5cd3cd3d590e3843056442 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27a56e73f1386078bc5f4cfc07f6a032 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_191c9c54c58038329a4309ade23ff2f0 |
| publicationDate | 2008-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2331260-C |
| titleOfInvention | Method and kit for detecting resistance to antiviral drugs |
| abstract | An assay and kit for the detection of phenotypic resistance of a retrovirus to a reverse transcriptase inhibitor drug in a biological sample. The assay is based on the direct analysis of the susceptibility of retroviral reverse transcriptase to inhibition by a reverse transcriptase inhibitor drug. The enzymatic activity of the reverse transcriptase is determined by measuring the DNA product produced when an RNA template and a first complementary DNA primer from a suitable region of the encephalomyocarditis virus genome are incubated with a biological sample containing reverse transcriptase in the presence of the dr ug to which resistance is being determined. The incubation mixture is reacted under conditions whereby the RNA template and the DNA primer will anneal and a DNA strand will be synthesized as an extension from the DNA primer if the reverse transcriptase in the samp le is resistant to and not inhibited by the drug. The DNA product is amplified using a second complementary DNA primer from the encephalomyocarditis virus genome and suitable PCR reagents and conditions, and the amplified product detected in accordance with method s known to those skilled in the art. Detection of the amplified DNA indicates resistance to the drug employed in the assay. |
| priorityDate | 1998-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 119.